Evidence map›Paper›PMID 25122196›Full record

ArticlePloS one2014

Epithelial and stromal microRNA signatures of columnar cell hyperplasia linking Let-7c to precancerous and cancerous breast cancer cell proliferation.

Sofie Björner, Paul A Fitzpatrick, Yaoyong Li, Craig Allred, Anthony Howell, Anita Ringberg, Håkan Olsson, Crispin J Miller, Håkan Axelson, Göran Landberg

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Down-regulation ofInternational journal of molecular epidemiology and genetics · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review on the Applications and Molecular Mechanisms of Xihuang Pill in Tumor Treatment.Evidence-based complementary and alternative medicine : eCAM · 2015
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Sofie BjörnerCenter for Molecular Pathology, Skåne University Hospital, Department of Laboratory Medicine Malmö, Lund University, Malmö, Sweden; Breakthrough Breast Cancer Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Paterson Institute for Cancer Research, The Christie National Health Service Foundation Trust, Manchester, United Kingdom; Sahlgrenska Cancer Center, Department of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
Paul A FitzpatrickSahlgrenska Cancer Center, Department of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
Yaoyong LiCancer Research UK Applied Computational Biology and Bioinformatics Group, Paterson Institute for Cancer Research, Manchester, United Kingdom.
Craig AllredDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri, United States of America.
Anthony HowellBreakthrough Breast Cancer Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Paterson Institute for Cancer Research, The Christie National Health Service Foundation Trust, Manchester, United Kingdom.
Anita RingbergDepartment of Plastic and Reconstructive Surgery, SUS Malmö, Institute of Clinical Sciences Malmö, Lund University, Malmö, Sweden.
Håkan OlssonDepartment of Oncology, Skåne University Hospital, Institute of Clinical Sciences Lund, Lund University, Lund, Sweden.
Crispin J MillerCancer Research UK Applied Computational Biology and Bioinformatics Group, Paterson Institute for Cancer Research, Manchester, United Kingdom.
Håkan AxelsonTranslational Cancer Research, Medicon Village, Department of Laboratory Medicine Malmö, Lund University, Lund, Sweden.
Göran LandbergCenter for Molecular Pathology, Skåne University Hospital, Department of Laboratory Medicine Malmö, Lund University, Malmö, Sweden; Breakthrough Breast Cancer Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Paterson Institute for Cancer Research, The Christie National Health Service Foundation Trust, Manchester, United Kingdom; Sahlgrenska Cancer Center, Department of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
Lund University · SECancer Research UK Manchester Institute · GBUniversity of Gothenburg · SEManchester Academic Health Science Centre · GBMedicon Village · SEWashington University in St. Louis · US

Funding

Cancer Research UK 15675
6 · The paper itself

Abstract

Columnar cell hyperplasia (CCH) is the earliest histologically identifiable breast lesion linked to cancer progression and is characterized by increased proliferation, decreased apoptosis and elevated oestrogen receptor α (ERα) expression. The mechanisms underlying the initiation of these lesions have not been clarified but might involve early and fundamental changes in cancer progression. MiRNAs are key regulators of several biological processes, acting by influencing the post-transcriptional regulation of numerous targets, thus making miRNAs potential candidates in cancer initiation. Here we have defined novel epithelial as well as stromal miRNA signatures from columnar cell hyperplasia lesions compared to normal terminal duct lobular units by using microdissection and miRNA microarrays. Let-7c were among the identified downregulated epithelial miRNAs and its functions were delineated in unique CCH derived cells and breast cancer cell line MCF-7 suggesting anti-proliferative traits potentially due to effects on Myb and ERα. MiR-132 was upregulated in the stroma surrounding CCH compared to stoma surrounding normal terminal duct lobular units (TDLUs), and overexpression of miR-132 in immortalized fibroblasts and in fibroblasts co-cultured with epithelial CCH cells caused substantial expression changes of genes involved in metabolism, DNA damage and cell motility. The miRNA signatures identified in CCH indicate early changes in the epithelial and stromal compartment of CCH and could represent early key alterations in breast cancer progression that potentially could be targeted in novel prevention or treatment schedules.

Indexed as

Breast NeoplasmsCell ProliferationEpithelial CellsFemaleHumansMicroRNAsPrecancerous ConditionsProto-Oncogene Proteins c-mybReceptors, EstrogenStromal CellsMicroRNAsProto-Oncogene Proteins c-mybReceptors, Estrogen

Identifiers

PMID25122196
PMCPMC4133372
OpenAlexW2003318880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.